PolyPEPI1018 Cancer Vaccine and TAS-102 for Patients With Advanced, Chemo-Refractory, Microsatellite-Stable Metastatic Colorectal Cancer: A Phase Ib Nonrandomized Study Using SEER 22 data, we analyzed ...

Enhertu significantly improves overall survival in HER2-positive metastatic gastric cancer compared to ramucirumab and paclitaxel. DESTINY-Gastric04 is the first phase 3 trial showing Enhertu's ...

Tislelizumab-jsgr approved with chemotherapy for HER2-negative gastric or gastroesophageal junction adenocarcinoma, showing significant survival benefits. RATIONALE-305 study demonstrated a 20% ...

Patients with ECOG performance status of 1 reported worse global health status, quality of life, and physical functioning than those with a status of 0. The RATIONALE-305 trial showed Tevimbra plus ...

Find out more about how AI has matched the diagnostic accuracy of expert endoscopists in detecting early gastric cancer.

The MATTERHORN trial showed improved EFS and OS with durvalumab plus chemotherapy in gastric/GEJ cancer patients compared to chemotherapy alone. Durvalumab treatment resulted in a higher pCR rate and ...

Please provide your email address to receive an email when new articles are posted on . Second-line trastuzumab deruxtecan-nxki significantly improved outcomes for advanced gastric cancers compared ...

Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma Patients had ...